Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Outset Medical (OM – Research Report) and ...

Allurion Technologies (ALUR) announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive ...

The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...